Short and Long-term Effects of Pulmonary Rehabilitation in Interstitial Lung Diseases: a Randomised Controlled Trial

Overview

Journal Respir Res

Specialty Pulmonary Medicine

Date 2018 Sep 22

PMID 30236104

Citations 39

Authors

Silvia Perez-Bogerd

Wim Wuyts

Veronica Barbier

Heleen Demeyer

Alain Van Muylem

Wim Janssens

Thierry Troosters

Affiliations

Soon will be listed here.

Abstract

Background: Few data are available on the long-term effect of pulmonary rehabilitation (PR) and on long PR programs in interstitial lung diseases (ILD). We aimed to evaluate the effects of PR on exercise capacity (6-Minute Walking Distance, 6MWD; Peak Work Rate, W), quality of life (St George's Respiratory Questionnaire, SGRQ), quadriceps force (QF) and objectively measured physical activity in ILD after the 6-month PR-program and after 1 year.

Methods: 60 patients (64 ± 11 years; 62% males; 23% with IPF) were randomly assigned to receive a 6 month-PR program or usual medical care.

Results: Exercise capacity, quality of life and muscle force increased significantly after the program as compared to control (mean,95%CI[ll to ul]; 6MWD + 72,[36 to 108] m; W 19, [8 to 29]%pred; SGRQ - 12,[- 19 to - 6] points; QF 10, [1 to 18] %pred). The gain was sustained after 1 year (6MWD 73,[28 to 118] m; Wmax 23, [10 to 35]%pred; SGRQ - 11,[- 18 to - 4] points; QF 9.5, [1 to 18] %pred). Physical activity did not change.

Conclusions: PR improves exercise tolerance, health status and muscle force in ILD. The benefits are maintained at 1-year follow-up. The intervention did not change physical activity.

Trial Registration: Clinicaltrials.gov NCT00882817 .

Citing Articles

Current status of pulmonary rehabilitation and impact on prognosis of patients with idiopathic pulmonary fibrosis in South Korea.

Nam J, Kim K, Rhee C, Choi J, Jo Y J Thorac Dis. 2025; 16(12):8379-8388.

PMID: 39831231 PMC: 11740027. DOI: 10.21037/jtd-24-1165.

Sarcopenia in interstitial lung disease.

Sheehy R, McCormack S, Fermoyle C, Corte T Eur Respir Rev. 2024; 33(174).

PMID: 39631931 PMC: 11615663. DOI: 10.1183/16000617.0126-2024.

Patient-centered care in pulmonary fibrosis: access, anticipate, and act.

Hofman D, Magri T, Moor C, Richeldi L, Wijsenbeek M, Waseda Y Respir Res. 2024; 25(1):395.

PMID: 39487454 PMC: 11531140. DOI: 10.1186/s12931-024-02997-7.

Functional status following pulmonary rehabilitation in people with interstitial lung disease: A systematic review and meta-analysis.

Rodrigues G, Santos R, Pinto R, Oliveira A, Marques A Chron Respir Dis. 2024; 21:14799731241255138.

PMID: 39440394 PMC: 11500222. DOI: 10.1177/14799731241255138.

Clinically important changes and adverse events with centre-based or home-based pulmonary rehabilitation in chronic respiratory disease: A systematic review and meta-analysis.

Bondarenko J, Dal Corso S, Dillon M, Singh S, Miller B, Kein C Chron Respir Dis. 2024; 21:14799731241277808.

PMID: 39187265 PMC: 11348370. DOI: 10.1177/14799731241277808.

References

Holland A, Hill C . Physical training for interstitial lung disease. Cochrane Database Syst Rev. 2008; (4):CD006322. DOI: 10.1002/14651858.CD006322.pub2. View

Spruit M, Singh S, Garvey C, ZuWallack R, Nici L, Rochester C . An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013; 188(8):e13-64. DOI: 10.1164/rccm.201309-1634ST. View

Watz H, Pitta F, Rochester C, Garcia-Aymerich J, ZuWallack R, Troosters T . An official European Respiratory Society statement on physical activity in COPD. Eur Respir J. 2014; 44(6):1521-37. DOI: 10.1183/09031936.00046814. View

de Vries J, Seebregts A, Drent M . Assessing health status and quality of life in idiopathic pulmonary fibrosis: which measure should be used?. Respir Med. 2000; 94(3):273-8. DOI: 10.1053/rmed.1999.0736. View

McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y . Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015; (2):CD003793. PMC: 10008021. DOI: 10.1002/14651858.CD003793.pub3. View

King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92. DOI: 10.1056/NEJMoa1402582. View

Haskell W, Lee I, Pate R, Powell K, Blair S, Franklin B . Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc. 2007; 39(8):1423-34. DOI: 10.1249/mss.0b013e3180616b27. View

Demeyer H, Louvaris Z, Frei A, Rabinovich R, de Jong C, Gimeno-Santos E . Physical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trial. Thorax. 2017; 72(5):415-423. PMC: 5520265. DOI: 10.1136/thoraxjnl-2016-209026. View

Kozu R, Senjyu H, Jenkins S, Mukae H, Sakamoto N, Kohno S . Differences in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Respiration. 2010; 81(3):196-205. DOI: 10.1159/000315475. View

10.

Gaunaurd I, Gomez-Marin O, Ramos C, Sol C, Cohen M, Cahalin L . Physical activity and quality of life improvements of patients with idiopathic pulmonary fibrosis completing a pulmonary rehabilitation program. Respir Care. 2014; 59(12):1872-9. DOI: 10.4187/respcare.03180. View

11.

Troosters T, Gosselink R, Decramer M . Six minute walking distance in healthy elderly subjects. Eur Respir J. 1999; 14(2):270-4. DOI: 10.1034/j.1399-3003.1999.14b06.x. View

12.

Vainshelboim B, Kramer M, Izhakian S, M Lima R, Oliveira J . Physical Activity and Exertional Desaturation Are Associated with Mortality in Idiopathic Pulmonary Fibrosis. J Clin Med. 2016; 5(8). PMC: 4999793. DOI: 10.3390/jcm5080073. View

13.

Huppmann P, Sczepanski B, Boensch M, Winterkamp S, Schonheit-Kenn U, Neurohr C . Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir J. 2012; 42(2):444-53. DOI: 10.1183/09031936.00081512. View

14.

Troosters T, Casaburi R, Gosselink R, Decramer M . Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 172(1):19-38. DOI: 10.1164/rccm.200408-1109SO. View

15.

Vainshelboim B, Oliveira J, Fox B, Soreck Y, Fruchter O, Kramer M . Long-term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis. Lung. 2015; 193(3):345-54. DOI: 10.1007/s00408-015-9703-0. View

16.

Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M . Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2009; 35(4):821-9. DOI: 10.1183/09031936.00005209. View

17.

Jackson R, Gomez-Marin O, Ramos C, Sol C, Cohen M, Gaunaurd I . Exercise limitation in IPF patients: a randomized trial of pulmonary rehabilitation. Lung. 2014; 192(3):367-76. DOI: 10.1007/s00408-014-9566-9. View

18.

Holland A, Hill C, Glaspole I, Goh N, McDonald C . Predictors of benefit following pulmonary rehabilitation for interstitial lung disease. Respir Med. 2011; 106(3):429-35. DOI: 10.1016/j.rmed.2011.11.014. View

19.

Holland A, Hill C, Conron M, Munro P, McDonald C . Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008; 63(6):549-54. DOI: 10.1136/thx.2007.088070. View

20.

du Bois R, Weycker D, Albera C, Bradford W, Costabel U, Kartashov A . Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2010; 183(9):1231-7. DOI: 10.1164/rccm.201007-1179OC. View